EVT Supplement 2017
The 2017 EVT supplement is available. Find topics like:
- Latest interim clinical results on post-market DES registry
- Economic analysis on DE technology
- Atherectomy combined with DCB
The state of peripheral drug-eluting technologies
by Michael R. Jaff, Do.
Interim results from the Münster Postmarket all-comers registry.
A look at the latest data on use of the Eluvia drug eluting stent in challenging SFA lesions.
by Theodosios Bisdas, MD,Phd
Twelve-Month Results from the RANGER-SFA Trial
What these findings tell us about the safety and efficacy of the Ranger drug-coated balloon.
with Dierk Scheinert, MD
Economic analysis supporting the use of Drug-Eluting Technologies in the Femoropopliteal Artery
These evolving modern therapies are showing promise in reducing health care costs while offering better outcomes.
by Konstantinos Katsanos, MSc, MD, PhD, EBIR
Clinical benefit of long-length Drug-Coated Balloons
The anatomic factors that make longer DCBs the ideal choice for treating longer, more difficult lesions.
by Gunnar Tepe, MD
Experience with Atherectomy and DCBs
The merits of a two-part approach in the SFA and popliteal artery.
by Ulrich Sunderdiek, MD, PhD
Experience with Drug-Eluting Technologies in BTK Interventions
Promising results for drug-eluting stent use in CLI patients with lesions below the knee.
by Hans Van Overhagen, MD, PhD, EBIR
New Technologies to solve the challenges of CLI
The unique features of this disease are finally being addressed with new devices.
by J.A. Mustapha, MD, and Fadi Saab, MD
WANT TO KNOW MORE?
Join our Drug-Eluting Technologies Community
Sign Up for Product Updates
Receive the latest news of Drug Eluting TechnologiesSIGN UP